A couple of weeks ago, the Boston Globe ran an article by Scott Kirsner, “The suburbs are cheaper, but they don’t have what Kendall Square has for biotechs: ...

Getting a pharma deal done is a critical growth step for any biopharmaceutical startup. In a previous post, I discussed a number of the preliminary steps in ...

The end customer for many biotech firms is often a larger biopharmaceutical company looking to build their pipeline or technology capabilities. It is quite r...

The conference business is alive and well – biotech entrepreneurs can easily spend significant time and money on scientific and business conventions. The cha...

Many scientific and technological innovations over the past decade have enabled a new type of biotech startup to operate successfully – the “semi-virtual”, h...

Some of the most impactful experiences I have had as CEO of two different companies occurred through my participation in confidential CEO peer groups or “for...

For thinly funded startups, grants can be an excellent source of early funding, leverage for an angel round, and a significant non-dilutive capital infusion....

Angel investors are significant players in the startup ecosystem who, through syndication with other angels, can invest amounts on par with investments made ...

Today, science-based startups can take advantage of a growing ecosystem that supports the efficient capital launch and operation of these exciting companies....